Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.51 |
| ▸ | MMP3 | P08254 | 7/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 2/20 | 0.51 |
| ▸ | MMP14 | P50281 | 2/20 | 0.51 |
| ▸ | RAF1 | P04049 | 12/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436315 | 1.00 | MMP2 (0.51) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6434274 | 0.94 | MMP2 (0.51) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6436812 | 0.94 | MMP2 (0.51) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6433657 | 0.93 | MMP2 (0.52) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6433803 | 0.93 | MMP2 (0.52) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6956213 | 0.92 | MMP2 (0.55) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6972399 | 0.92 | MMP2 (0.55) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6435284 | 0.90 | MMP2 (0.63) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6434450 | 0.86 | MMP2 (0.56) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6437467 | 0.85 | MMP2 (0.51) | MMP2MMP3MMP1MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1181017-B1 | METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6511993-B1 | Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MMP2 19/4885MMP3 28/4885MMP1 1/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | MMP2 19/4885MMP3 28/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.